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Abstract
Background
New diagnostic tools are urgently needed to interrupt the transmission of tubercu-
losis and multidrug-resistant tuberculosis. Rapid, sensitive detection of tuberculosis 
and multidrug-resistant tuberculosis in sputum has been demonstrated in proof-
of-principle studies of the microscopic-observation drug-susceptibility (MODS) as-
say, in which broth cultures are examined microscopically to detect characteristic 
growth.
Methods
In an operational setting in Peru, we investigated the performance of the MODS as-
say for culture and drug-susceptibility testing in three target groups: unselected pa-
tients with suspected tuberculosis, prescreened patients at high risk for tuberculosis 
or multidrug-resistant tuberculosis, and unselected hospitalized patients infected 
with the human immunodeficiency virus. We compared the MODS assay head-to-
head with two reference methods: automated mycobacterial culture and culture on 
Löwenstein–Jensen medium with the proportion method.
Results
Of 3760 sputum samples, 401 (10.7%) yielded cultures positive for Mycobacterium tuber-
culosis. Sensitivity of detection was 97.8% for MODS culture, 89.0% for automated 
mycobacterial culture, and 84.0% for Löwenstein–Jensen culture (P<0.001); the medi-
an time to culture positivity was 7 days, 13 days, and 26 days, respectively (P<0.001), 
and the median time to the results of susceptibility tests was 7 days, 22 days, and 
68 days, respectively. The incremental benefit of a second MODS culture was minimal, 
particularly in patients at high risk for tuberculosis or multidrug-resistant tubercu-
losis. Agreement between MODS and the reference standard for susceptibility was 
100% for rifampin, 97% for isoniazid, 99% for rifampin and isoniazid (combined 
results for multidrug resistance), 95% for ethambutol, and 92% for streptomycin (kap-
pa values, 1.0, 0.89, 0.93, 0.71, and 0.72, respectively).
Conclusions
A single MODS culture of a sputum sample offers more rapid and sensitive detection 
of tuberculosis and multidrug-resistant tuberculosis than the existing gold-standard 
methods used.
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E
very year, 1.7 million people die of 
tuberculosis, a curable disease.1 The poor 
are disproportionately affected, and tuber-
culosis further impoverishes individual people 
and societies. Goal 6 of the Millennium Develop-
ment Goals of the United Nations includes the 
halting and reversal of the rising incidence of tu-
berculosis, and the Stop TB Partnership aims to 
halve the prevalence of tuberculosis and result-
ing deaths by 2015.2 Existing control strategies 
miss important opportunities to interrupt trans-
mission. Improved tuberculosis detection and early 
identification of multidrug-resistant tuberculo-
sis are key gaps.
Sputum-smear–based diagnosis under the Di-
rect Observation of Therapy (Short Course) (DOTS) 
strategy of the World Health Organization for 
global tuberculosis control misses half of inci-
dent cases at first presentation. Transmission 
continues until cases are detected with more ad-
vanced (smear-positive) disease and are correctly 
treated. Multidrug-resistant tuberculosis increas-
es morbidity and mortality and, through treat-
ment failure,3 facilitates continuing transmis-
sion from patients who (like their health care 
providers) wrongly believe they are being cured. 
The use of treatment failure to prompt drug-
susceptibility testing relies on the same illness-
threshold effect as waiting for smears to become 
positive in patients with negative smears.4 Both 
scenarios could be addressed by appropriate new 
diagnostics.5
The microscopic-observation drug-susceptibil-
ity (MODS) assay for the detection of tuberculosis 
and multidrug-resistant tuberculosis, directly from 
sputum, relies on three principles: first, that 
Mycobacterium tuberculosis grows faster in liquid me-
dium than in solid medium; second, that charac-
teristic cord formation can be visualized micro-
scopically in liquid medium at an early stage; and 
third, that the incorporation of drugs permits 
rapid and direct drug-susceptibility testing con-
comitantly with the detection of bacterial growth.
In proof-of-principle studies, the MODS assay 
distinguished patients with tuberculosis from 
healthy controls.6,7 In accordance with recommen-
dations,8 we undertook an operational evaluation 
of the MODS assay in order to answer two ques-
tions: How well does it distinguish between pa-
tients with and those without active tuberculosis 
among those with suspected tuberculosis? Among 
patients with active tuberculosis, how well does 
it distinguish drug-resistant disease from drug-
sensitive disease?
Given the challenges of the evaluation of tech-
niques for the diagnosis of tuberculosis,9-13 our 
study was conducted in accordance with the emerg-
ing consensus about the design and reporting 
of diagnostic-test evaluations14-18 and the min-
imum standards required for diagnostic trials of 
tuberculosis.8,19,20
Methods
Study Patients and Setting
The study was conducted in Lima, Peru, from April 
2003 through July 2004 in three target groups, 
with consecutive recruitment. The first group con-
sisted of otherwise unselected patients who pre-
sented with suspected tuberculosis to the Na-
tional TB Programme at 10 government clinics 
in north Lima. The second consisted of patients 
who presented with suspected tuberculosis to the 
National TB Programme at five government clin-
ics in east Lima and who were at high risk for 
tuberculosis or multidrug-resistant tuberculosis. 
Inclusion in this group required the presence of 
one or more constitutional symptoms (fever, weight 
loss, night sweats, hemoptysis) or one risk fac-
tor for tuberculosis or multidrug-resistant tuber-
culosis (prior treatment for tuberculosis, known 
contact with a patient with tuberculosis, infection 
with human immunodeficiency virus [HIV], em-
ployment as a health care or prison worker, hos-
pitalization during the previous year, or any pre-
vious incarceration). The third group consisted 
of otherwise unselected hospitalized patients with 
HIV infection at two Lima hospitals, regardless 
of the diagnosis on admission. Exclusion criteria 
for all groups were an age under 18 years or an 
inability or unwillingness to give written informed 
consent. Study protocol and consent forms were 
approved by the institutional review boards of Uni-
versidad Peruana Cayetano Heredia, Asociación 
Benéfica PRISMA, Dirección de Salud–III Lima 
Norte and Dirección de Salud–IV Lima Este (re-
gional Ministry of Health), Hospital Nacional 
Hipolito Unanue, Hospital Nacional General Ar-
zobispo Loayza, Johns Hopkins Bloomberg School 
of Public Health, and Imperial College London. 
Sample Collection
Patients with suspected tuberculosis and pre-
screened patients at high risk for tuberculosis or 
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multidrug-resistant tuberculosis submitted two 
samples of sputum to the National TB Programme 
for routine Ziehl–Neelsen staining and consent-
ed to their subsequent use in the study (at Univer-
sidad Peruana Cayetano Heredia). Among the hos-
pitalized patients with HIV infection, two samples 
per patient were collected exclusively for the study, 
of which 20 were from gastric washing in 15 pa-
tients who were unable to provide adequate spu-
tum samples. 
Patients with suspected tuberculosis and pre-
screened patients at high risk for tuberculosis or 
multidrug-resistant tuberculosis who were eligible 
for the study were not recruited if they presented 
at the clinic outside of normal working hours 
(>90% of excluded patients), declined to partici-
pate (<5%), or if the clinic staff were unavailable 
(<5%). Numbers of eligible patients were derived 
from data extracted from National TB Programme 
log entries during the recruitment period; the 
numbers may have been overestimated, since fol-
low-up patients (who were ineligible) were not 
always clearly identified. Of the 25 hospitalized 
patients with HIV infection who were eligible 
but not recruited, more than 90% were incapable 
of providing informed consent, owing to their 
clinical condition, or were receiving ongoing treat-
ment for tuberculosis. Most, but not all, patients 
submitted two sputum samples.
Laboratory Methods
Detection of M. tuberculosis
Sputum samples were decontaminated accord-
ing to the sodium hydroxide–N-acetyl-L-cysteine 
method.21 An aliquot was used for microscopical 
examination of auramine-stained sputum smears, 
and the remainder was used for parallel Löwen-
stein–Jensen culture, automated mycobacterial 
culture, and MODS culture (see Fig. I in the Sup-
plementary Appendix, available with the full text 
of this article at www.nejm.org). Löwenstein–
Jensen culture and automated mycobacterial cul-
ture with the use of the MBBacT system (bioMéri-
eux) were selected because they are reference 
methods commonly used in developing and in-
dustrialized countries, respectively. After inocu-
lation of 250 μl of decontaminant, Löwenstein–
Jensen slants were incubated at 37°C and examined 
twice weekly from day 7 through day 60.21 MBBacT 
bottles were inoculated with 500 μl of decontam-
inant, and cultures were monitored continuously 
for 42 days according to the recommendations of 
the manufacturer.
The MODS assay was performed as described 
previously.6,7 Briefly, broth cultures were prepared 
in 24-well tissue-culture plates (Becton Dickin-
son), each containing 720 μl of decontaminant, 
Middlebrook 7H9 broth (Becton Dickinson), ox-
alic acid, albumin, dextrose, and catalase (OADC) 
(Becton Dickinson), and polymyxin, amphoteri-
cin B, nalidixic acid, trimethoprim, and azlocil-
lin (PANTA) (Becton Dickinson). For each sam-
ple, 12 wells were used: in 4 control wells, no drug 
was added, and each of the remaining 8 wells 
contained one of four drugs at one of two con-
centrations tested. The cultures were examined 
under an inverted light microscope at a magni-
fication of 40× every day (except Saturday and 
Sunday) from day 4 to day 15, on alternate days 
from day 16 to day 25, and twice weekly from 
day 26 to day 40. To minimize cross-contamina-
tion and occupational exposure, plates were per-
manently sealed inside plastic ziplock bags after 
inoculation and were subsequently examined with-
in the bag. Positive cultures were identified by cord 
formation, characteristic of M. tuberculosis growth, 
in liquid medium in drug-free control wells, as 
described previously.6,7,22 Nontuberculous myco-
bacteria were recognized by their lack of cording 
or, for M. chelonae (which is the only nontubercu-
lous mycobacteria that does form cords), by rapid 
overgrowth by day 5. Fungal or bacterial contami-
nation was recognized by rapid overgrowth and 
clouding in wells.
If contamination was detected, the original 
sample was cultured again after being decontami-
nated once more. Spacer oligonucleotide typing 
(spoligotyping), polymerase chain reaction with 
multiple primers,23 or both were applied to all iso-
lates from each of the three types of cultures in 
order to confirm the presence of M. tuberculosis.
Drug-Susceptibility Testing
Direct drug-susceptibility testing was performed 
with the use of the MODS assay, as previously 
described.6,7 Growth in drug-free control wells but 
not in drug-containing wells indicated suscep-
tibility. The drug concentrations used were as 
follows: isoniazid, 0.1 and 0.4 μg per milliliter; 
rifampin, 1 and 2 μg per milliliter; ethambutol, 
2.5 and 5.0 μg per milliliter; and streptomycin, 
2 and 6 μg per milliliter. Drug-sensitive control 
strains were tested daily. Indirect drug-suscep-
tibility testing was performed with the use of the 
proportion method21 for isolates from Löwen-
stein–Jensen culture (by an external laboratory) 
The New England Journal of Medicine 
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and with the automated MBBacT system24-29 for 
isolates from the automated mycobacterial cul-
ture. For purposes of discrepant analysis, the mi-
croplate alamar blue assay30-35 was performed in 
parallel, both for all Löwenstein–Jensen isolates 
and for isolates from drug-free control wells in 
the MODS assay. All procedures were performed 
by six staff members of the mycobacteriology labo-
ratory who were unaware of the results of the 
other tests.
Statistical Analysis
Data were analyzed with the use of Stata 7 soft-
ware, with the sample as the unit of analysis, to 
reflect the operational performance of a routine 
service laboratory. The Wilcoxon signed-rank test 
was used to compare the times to each end point 
among the three methods. A P value of less than 
0.05 was used to indicate statistical significance. 
The concordance of susceptibility results was de-
termined with the use of the sensitivity, specific-
ity, and positive and negative predictive values for 
the detection of resistance (with 95% confidence 
intervals [CIs]), as well as with kappa values.
To address the inherent difficulty of evaluat-
ing a test that is more sensitive than the refer-
ence tests, and to minimize incorporation bias 
(the use of results from the investigational test 
as part of the reference result), we previously 
undertook a comprehensive microbiologic, mo-
Table 1. Demographic Characteristics, Prevalence of Disease, and Sensitivity, Specificity, and Predictive Values for the Detection 
of Mycobacterium tuberculosis in Sputum.*
Characteristic
All Patients
(N = 1980)
Patients with Suspected 
Tuberculosis
(N = 1570)
Prescreened Patients 
at High Risk for 
Tuberculosis or 
Multidrug-Resistant 
Tuberculosis
(N = 253)
Hospitalized Patients 
with HIV Infection
(N = 157)
Median age — yr 32 32 34 32
Female sex — % 58.1 60.2 56.6 38.5
Positive smear for acid-fast bacilli — 
no./no. of samples (%)
220/3757 (5.9) 142/3017 (4.7) 55/446 (12.3) 23/294 (7.8)
Culture positive for M. tuberculosis — 
no./no. of samples (%)
  401/3757 (10.7) 263/3017 (8.7) 91/446 (20.4)   47/294 (16.0)
MODS assay — % (95% CI)
Sensitivity 97.8 (97.3–98.2) 97.3 (96.8–97.9) 98.9 (97.9–99.9) 97.9 (96.2–99.5)
Specificity 99.6 (99.5–99.8) 99.7 (99.5–99.9) 99.2 (98.3–100) 100 (100–100)
PPV 97.0 (96.5–97.6) 96.6 (96.0–97.3) 96.8 (95.1–98.4) 100 (100–100)
NPV 99.7 (99.6–99.9) 99.8 (99.6–99.9) 99.7 (99.2–100) 99.6 (98.9–100)
Automated mycobacterial culture — % 
(95% CI)
Sensitivity 89.0 (88.0–90.0) 87.8 (86.7–89.0) 92.3 (89.8–94.8) 89.4 (85.8–92.9)
Specificity 99.9 (99.8–100) 99.9 (99.8–100) 99.7 (99.2–100) 100 (100–100)
PPV 98.9 (98.6–99.2) 98.7 (98.3–99.1) 98.8 (97.8–99.8) 100 (100–100)
NPV 98.7 (98.3–99.1) 98.9 (98.5–99.2) 98.1 (96.8–99.3) 98.0 (96.4–99.6)
Löwenstein–Jensen culture — % (95% CI)
Sensitivity 84.0 (82.9–85.2) 82.5 (81.2–83.9) 89.0 (86.1–91.9) 83.0 (78.7–87.3)
Specificity 100 (99.9–100) 100 (99.9–100) 100 (100–100) 100 (100–100)
PPV 99.7 (99.5–99.9) 99.5 (99.3–99.8) 100 (100–100) 100 (100–100)
NPV 98.1 (97.7–98.6) 98.4 (97.9–98.8) 97.3 (95.8–98.8) 96.9 (94.9–98.9)
* For sensitivity and specificity of detection and predictive-value calculations, a positive reference result was defined as a positive culture ac-
cording to at least one method for which cross-contamination had been conclusively ruled out; a negative reference result was defined as 
any sample in which all three culture methods yielded negative results or two were negative and the third indeterminate, owing to repeated 
bacterial or fungal overgrowth, or a sample for which cross-contamination was demonstrated to be the only positive cause of a positive cul-
ture.36 Upper 95% CIs exceeding 100% were rounded to 100%. PPV denotes positive predictive value, and NPV negative predictive value.
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Figure 2. Incremental Benefit of One and Two Sputum 
Cultures as Compared with Sputum-Smear Microscopy.
The percentage of cases detected during examination 
of the first smear or culture is shown, as well as the 
additional (not total) percentage detected during ex-
amination of a second smear or culture. For patients 
with suspected tuberculosis (Panel A) and prescreened 
patients at high risk for tuberculosis or multidrug-
resistant tuberculosis (Panel B), examination of smears 
stained with the Ziehl–Neelsen (Z-N) stain was per-
formed at the local laboratory of the National TB Pro-
gramme before the sample was retrieved for study pur-
poses. For samples from the hospitalized patients with 
HIV infection (Panel C), microscopical examination of 
sputum smears stained with auramine but not Z-N 
stain was performed at Universidad Peruana Cayetano 
Heredia, because these patients were not recruited 
through the National TB Programme. L-J denotes Löw-
enstein–Jensen.
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lecular, and epidemiologic investigation of the 
discordant cultures.36 We identified 17 cross-con-
taminated cultures (12 MODS cultures, 4 auto-
mated mycobacterial cultures, and 1 Löwenstein–
Jensen culture) from 14 samples. For sensitivity 
and specificity of detection and predictive-value 
calculations for each of the three methods, a 
positive reference result was defined as a positive 
culture according to at least one method for which 
cross-contamination had been conclusively ruled 
out.36 A negative reference result was defined as 
any sample in which all three culture methods 
yielded negative results or in which two were nega-
tive and the third indeterminate, owing to repeated 
bacterial or fungal overgrowth, or a sample for 
which cross-contamination was demonstrated 
to be the only cause of the positive culture.36
Thus, the 17 false positive cultures were de-
fined as positive in calculations of performance 
characteristics for the relevant methods, but the 
reference result for the 14 samples was deter-
mined to be negative. McNemar’s χ  2 test was used 
to compare the sensitivities of detection of the 
three methods.
definition of reference susceptibility test 
results
Concordant results from automated mycobacte-
rial culture and the proportion method were 
regarded as the reference result for drug suscep-
tibility. Discordant results from automated my-
cobacterial culture and the proportion method 
were resolved by means of discrepant analysis, 
with the use of the two parallel results from the 
microplate alamar blue assay. If both results from 
this assay agreed, that result was used as the ref-
erence result; if not, the strain was designated in-
determinate (see Table I in the Supplementary 
Appendix).
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Results
Patients and Samples
Recruitment of patients and culture results are 
shown in Figure 1. Demographic characteristics 
and tuberculosis diagnoses are shown in Table 1 
according to study group.
Sensitivity and Specificity of Detection
Of the 3760 sputum samples collected, 401 (10.7%) 
were positive for M. tuberculosis cultures, 3356 were 
negative, and 3 were indeterminate (and were re-
moved from analysis), because all three types of 
cultures were repeatedly contaminated by bacte-
rial overgrowth. MODS culture had a greater over-
all sensitivity of detection than either automated 
mycobacterial culture or Löwenstein–Jensen culture 
(97.8%, 89.0%, and 84.0%, respectively; P<0.001); 
this difference was maintained in all groups. The 
overall specificity of detection was 99.6% for MODS 
culture, 99.9% for automated mycobacterial cul-
ture, and 100.0% for Löwenstein–Jensen culture. 
Predictive values and data according to group are 
shown in Table 1, and in Figure II of the Supple-
mentary Appendix.
Added Value of Second Culture 
for Sensitivity of Detection
The incremental benefit of a second smear for 
acid-fast bacilli and a second sputum culture is 
shown in Figure 2. A second MODS culture de-
tected an additional 8.2% of cases among patients 
with suspected tuberculosis but offered no add-
ed value among prescreened patients at high risk 
for tuberculosis or multidrug-resistant tubercu-
losis.
Time to Culture Positivity
Of the 401 sputum samples positive for M. tuber-
culosis, 325 were culture-positive according to all 
three methods and were thus included in the 
head-to-head analysis of time to culture positiv-
ity (Fig. 3). The median time to culture positivity 
was significantly shorter for MODS than for the 
automated mycobacterial or Löwenstein–Jensen 
cultures (7 days [interquartile range, 6 to 8] vs. 
13 days [interquartile range, 10 to 16] and 26 
days [interquartile range, 21 to 33], respectively; 
P<0.001). Smear status had a clinically unimport-
ant, though significant, effect on time to culture 
positivity in MODS culture (median, 6 days for a 
smear-positive sample vs. 7 days for a smear-
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Figure 3. Cumulative Percentages of the Time to Culture Positivity for 325 
Culture-Positive Samples According to Culture Method (Panel A) and the 
Effect of the Quantitative Status of Sputum Smears for Acid-Fast Bacilli 
(Panels B, C, and D). 
The percentages of cultures that were positive at days 7, 14, and 21 were 74%, 
99%, and 100%, respectively, in MODS culture; 7%, 62%, and 89% in auto-
mated mycobacterial culture; and 0%, 5%, and 28% in Löwenstein–Jensen 
(L-J) culture (Panel A). In Panels B, C, and D, “auramine smear –” was defined 
by the presence of fewer than 10 acid-fast bacilli per 100 fields, “1+” 10 to 99 
acid-fast bacilli per 100 fields, “2+” 1 to 10 acid-fast bacilli per field, and “3+” 
more than 10 acid-fast bacilli per field. One field was equivalent to the ex-
amination of one carbol-fuchsin–stained smear at a magnification of 1000×.
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negative sample; P<0.001). Though samples that 
were culture-negative (69) or contaminated (7) 
according to at least one method were excluded 
from this analysis, results were unchanged by 
their inclusion (data not shown).
Bacterial and Fungal Contamination 
of Cultures
The median time from sample collection to sam-
ple processing was 3 days, and most but not all 
samples were refrigerated en route. At least one 
culture per sample was contaminated in 739 of 
3760 samples (20.0%), though in only 63 samples 
(1.7%) were all cultures by the three methods con-
taminated. The proportion of initially contami-
nated samples was 8.1% (95% CI, 7.2 to 9.0) for 
MODS culture, 4.4% (95% CI, 3.8 to 5.3) for au-
tomated mycobacterial culture, and 14.2% (95% 
CI, 13.1 to 15.3) for Löwenstein–Jensen culture. 
However, ultimately contaminated (indetermi-
nate) cultures were less frequent in MODS cul-
ture (6 cultures, 0.2%) than in either automated 
mycobacterial culture (11 cultures, 0.3%; P  =  0.01) 
or Löwenstein–Jensen culture (55 cultures, 1.5%; 
P<0.001). The median time from initial process-
ing of samples to the results of culture testing for 
initially contaminated cultures was shorter for 
MODS culture (24 days; 95% CI, 19 to 28) than 
for automated mycobacterial culture (32 days; 95% 
CI, 25 to 39; P  =  0.03) or Löwenstein–Jensen cul-
ture (50 days; 95% CI, 44 to 56; P<0.001). Positive 
MODS cultures that were contaminated but able 
to be evaluated accounted for less than 2.5% of 
all positive cultures for the assay.
Table 2. Susceptibility Results from the MODS Assay and Concordance with the Gold-Standard Methods.*
Measure All Patients
Patients with Suspected 
Tuberculosis
Prescreened Patients 
at High Risk 
for Tuberculosis or 
Multidrug-Resistant 
Tuberculosis
Hospitalized Patients 
with HIV Infection
Rifampin, 1 μg/ml
No. of samples 338
Resistant samples — % (95% CI) 10.7 (7.4–13.9) 11.0 (6.8–15.1) 13.8 (6.2–21.3) 2.6 (0–7.5)
Kappa value 1.0 1.0 1.0 1.0
Sensitivity — % (95% CI) 100 (100–100) 100 (100–100) 100 (100–100) 100 (100–100)
Specificity — % (95% CI) 100 (100–100) 100 (100–100) 100 (100–100) 100 (100–100)
PPV — % (95% CI) 100 (100–100) 100 (100–100) 100 (100–100) 100 (100–100)
NPV — % (95% CI) 100 (100–100) 100 (100–100) 100 (100–100) 100 (100–100)
Isoniazid, 0.4 μg/ml
No. of samples 334
Resistant samples — % (95% CI) 19.5 (15.2–23.7) 14.4 (9.7–19.0) 30.4 (20.2–40.5) 25.6 (11.9–39.4)
Kappa value 0.89 0.92 0.84 0.86
Sensitivity — % (95% CI) 84.6 (80.8–88.5) 90.3 (86.4–94.3) 79.2 (70.2–88.1) 80.0 (67.5–92.6)
Specificity — % (95% CI) 99.6 (99.0–100) 99.5 (98.5–100) 100 (100–100) 100 (100–100)
PPV — % (95% CI) 98.2 (96.8–99.6) 96.6 (94.1–99.0) 100 (100–100) 100 (100–100)
NPV — % (95% CI) 96.4 (94.4–98.4) 98.4 (96.7–100) 91.7 (85.6–97.8) 91.7 (85.6–97.8)
Rifampin and isoniazid†
No. of samples 334
Resistant samples — % (95% CI) 10.4 (7.1–13.6) 10.5 (6.4–14.6) 13.8 (6.2–21.3) 2.6 (0–7.5)
Kappa value 0.93 0.95 0.89 1.0
Sensitivity — % (95% CI) 88.6 (85.2–92.0) 91.3 (87.6–95.0) 81.8 (73.3–90.3) 100 (100–100)
Specificity — % 100 (100–100) 100 (100–100) 100 (100–100) 100 (100–100)
PPV — % 100 (100–100) 100 (100–100) 100 (100–100) 100 (100–100)
NPV — % (95% CI) 98.7 (97.5–99.9) 99.0 (97.6–100) 97.1 (93.5–100) 100 (100–100)
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Direct Drug-Susceptibility Testing
Valid drug-susceptibility testing in the MODS as-
say depends on the observed growth of M. tuber-
culosis in all four control wells, as was the case for 
349 of 392 positive MODS cultures (89.0%). Of the 
43 samples for which drug-susceptibility testing 
in the MODS assay was not possible, 28 (65.1%) 
were culture-negative according to automated my-
cobacterial culture and Löwenstein–Jensen culture. 
Resistance to rifampin was detected in 10.7% of 
all samples; to isoniazid, in 19.5%; to rifampin and 
isoniazid (combined to test for multidrug resis-
tance), in 10.4%; to ethambutol, in 10.1%; and to 
streptomycin, in 21.4% (Table 2). The proportion 
of samples for which susceptibility results agreed 
between MODS culture and the gold-standard 
methods was 100% for rifampin, 96.7% for iso-
niazid, 98.8% for rifampin and isoniazid, 95.4% 
for ethambutol, and 91.7% for streptomycin. Over-
all median times from initial sample processing 
to the results of drug-susceptibility testing were 
7 days for MODS culture, 22 days for automated 
mycobacterial culture, and 68 days for Löwen-
stein–Jensen culture.
Discussion
This operational study extends and provides sup-
port for the findings of earlier proof-of-principle 
studies6,7,22,37 and demonstrates that the MODS 
assay outperforms the gold-standard reference 
methods of developing and industrialized coun-
tries. For all three study groups, the MODS assay 
detected M. tuberculosis in sputum with greater 
sensitivity and speed and reliably identified mul-
tidrug-resistant tuberculosis strains in less time 
than did Löwenstein–Jensen or automated myco-
bacterial cultures. These data indicate that the 
Table 2. (Continued.) 
Measure All Patients
Patients with Suspected 
Tuberculosis
Prescreened Patients 
at High Risk 
for Tuberculosis or 
Multidrug-Resistant 
Tuberculosis
Hospitalized Patients 
with HIV Infection
Ethambutol, 2.5 μg/ml
No. of samples 327
Resistant samples — % (95% CI) 10.1 (6.8–13.4) 10.8 (6.6–14.9) 6.6 (1.0–12.2) 13.5 (2.5–24.5)
Kappa value 0.71 0.78 0.71 0.3
Sensitivity — % (95% CI) 63.6 (58.4–68.9) 69.6 (63.4–75.7) 80.0 (71.0–89.0) 20.0 (7.1–32.9)
Specificity — % (95% CI) 99.0 (97.9–100) 99.5 (98.5–100) 97.2 (93.5–100) 100 (100–100)
PPV — % (95% CI) 87.5 (83.9–91.1) 94.1 (91.0–97.3) 66.7 (56.1–77.3) 100 (100–100)
NPV — % (95% CI) 96.0 (93.9–98.2) 96.5 (94.0–98.9) 98.6 (95.9–100) 88.9 (78.8–99.0)
Streptomycin, 2 μg/ml
No. of samples 327
Resistant samples — % (95% CI) 21.4 (17.0–25.9) 19.3 (14.0–24.5) 24.1 (14.6–33.5) 28.6 (13.6–43.5)
Kappa value 0.72 0.72 0.70 0.77
Sensitivity — % (95% CI) 65.7 (60.6–70.9) 63.4 (57.0–69.9) 68.4 (58.2–78.7) 70 (54.8–85.2)
Specificity — % (95% CI) 98.8 (97.7–100) 99.4 (98.4–100) 96.7 (92.7–100) 100 (100–100)
PPV — % (95% CI) 93.9 (91.3–96.5) 96.3 (93.8–98.8) 86.7 (79.2–94.2) 100 (100–100)
NPV — % (95% CI) 91.4 (88.3–94.4) 91.9 (88.3–95.6) 90.6 (84.2–97.1) 89.3 (79.0–99.5)
* For susceptibility testing by the MODS assay, 349 samples were available; the number included in the analysis for each drug varied owing 
to differences in the rates of culture positivity and to occasional contamination. Two concentrations were examined for each drug; of sus-
ceptibility-test cultures in each case, one concentration was clearly superior, with no useful information gained from the second concentra-
tion (data not shown). The percentage of samples that were resistant was determined by gold-standard reference tests (see Table I in the 
Supplementary Appendix). The kappa statistic describes the strength of agreement beyond that due to chance between data from the 
MODS assay and the reference results, as follows: 0.00 to 0.20, slight; 0.21 to 0.40, fair; 0.41 to 0.60, moderate; 0.61 to 0.80, substantial; 
and 0.81 to 1.00, high. Sensitivity, specificity, positive predictive values (PPVs), and negative predictive values (NPVs) are for the detection 
of drug resistance. Upper 95% CIs exceeding 100% were rounded to 100%.
† Results for rifampin and isoniazid were combined in analyses for multidrug resistance. 
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MODS assay could be considered for use in ap-
propriate settings.
Our study was designed to address conven-
tional pitfalls.8,15,18,20,38 Specifically, it was per-
formed in an appropriately broad group of pa-
tients with or without disease and in pertinent 
patient groups (without selection bias); all tests 
were performed in all patients (preventing veri-
fication bias); and all results were interpreted by 
staff members who were unaware of the other test 
results, using appropriate gold-standard reference 
methods for comparison.
The robustness of our study derives from its 
operational, real-world design. Meticulous resolu-
tion of discordant results is essential when an in-
vestigational diagnostic method is more sensitive 
than existing reference standards. Use of two es-
tablished reference methods for comparison and 
two samples per patient facilitated the rigorous 
definition of true positive results, addressing the 
problem of incorporation bias. The high speci-
ficity and infrequent cross-contamination in the 
MODS assay36 relate to the containment of the 
plates in ziplock bags and the absence of manipu-
lation after inoculation, which also improve bio-
logic security.
The greater sensitivity and speed of detection 
in MODS culture than in the gold standards were 
predicted on the basis of previous studies.6,7,37 The 
increased sensitivity of liquid medium has long 
been known, and a discerning human eye can 
scrutinize cultures better than can automated sys-
tems with their use of necessarily rigid cutoff val-
ues. It is simpler to recognize the characteristic 
cord formation than to read a malarial smear; 
within 1 week, students training in our laboratory 
can comfortably and accurately read one well per 
minute, considerably faster than the time it takes 
to read a smear for acid-fast bacilli. Training in 
the MODS assay can be completed in less than 
2 weeks (similar to training in Löwenstein–Jen-
sen and automated mycobacterial cultures; train-
ing in drug-susceptibility testing with the pro-
portion method takes several months). Beyond 
standard laboratory equipment, automated myco-
bacterial culture requires computer-linked auto-
mated culture incubators, whereas MODS culture 
requires only an inverted light microscope. As 
purchased by us, the cost of $2 per sample for 
MODS culture compares favorably with the $6 
cost per sample for Löwenstein–Jensen culture 
and the proportion method and the cost of $52 
per sample for automated mycobacterial culture; 
however, labor costs may be higher for MODS 
culture.
Increased sensitivity carries the risk of increased 
bacterial overgrowth (for MODS culture and au-
tomated mycobacterial culture), though even after 
repeated decontamination, the sensitivity and spec-
ificity of MODS culture were unaffected. High 
speed, sensitivity, and specificity, and the require-
ment for only one culture, all enhance tuberculo-
sis rule-out procedures and potentially simplify 
tuberculosis-screening algorithms for use in pa-
tients with HIV infection before the initiation of 
prophylactic treatment with isoniazid. If a MODS 
culture is negative on day 15, there is a 99.7% 
chance that the sample is truly culture-negative. 
Thus, we believe that a negative MODS culture can 
be discarded after 3 weeks.
In settings with a high tuberculosis burden, 
the only susceptibility data that are likely to effect 
a change in therapy at the programmatic level are 
those for the detection of multidrug-resistant 
tuberculosis, for which the performance of the 
MODS assay is highly reliable and rapid (medi-
an time to the results of susceptibility testing, 
7 days), providing clinically important informa-
tion in a meaningful time frame. Although direct 
drug-susceptibility testing is conventionally viewed 
with suspicion — indirect testing of cultured 
strains is preferred — our data refute that view 
for rifampin and isoniazid in the MODS assay. 
However, susceptibility testing for M. tuberculosis 
is complex, and concordance among even regional 
laboratories performing gold-standard testing is 
particularly variable for ethambutol and strepto-
mycin.39 Our findings for these two drugs agreed 
with previous data for the MODS assay,7 demon-
strating insufficient concordance of the assay (at 
least in its current format) with gold standards to 
recommend usage.
Our study defines strengths and redundancies 
in the first-generation MODS assay and should en-
able the development of a streamlined, clinically 
useful method. The use of fewer wells per sample 
than we used — two wells with no drug (to ensure 
high specificity), one with rifampin (1 μg per mil-
liliter), and one with isoniazid (0.4 μg per millili-
ter) — reduces costs by 40% but does not affect 
performance. The MODS assay is “laboratory free-
ware,” not a commercial product or a kit. Any labo-
ratory that is adequately biologically secured, has 
an incubator and a centrifuge, and is capable of 
The New England Journal of Medicine 
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microscopy can safely perform MODS culture. All 
ingredients are available from major laboratory 
suppliers.
Downstream effects on patient care are the 
litmus test of the utility of a new method, and the 
added value will therefore depend on context and 
strategy for implementation. In countries where 
smear-negative tuberculosis is frequently diag-
nosed and treated empirically, the incremental 
benefit of MODS culture on case detection, as com-
pared with the smear alone, would be less than 
that in Peru, where only 21% of treated cases are 
smear-negative and where MODS culture has re-
cently been incorporated into Ministry of Health 
guidelines (www.minsa.gob.pe/normaslegales/
2006/RM383-2006.pdf). However, the high spec-
ificity rate would save patients and society money 
by minimizing overtreatment, and the early detec-
tion and treatment of multidrug-resistant tuber-
culosis would interrupt transmission. Equity in the 
access to high-performance techniques to diag-
nose tuberculosis thus benefits both individual 
health40,41 and public health. Despite the low cost 
per sample, in many resource-limited settings with 
a high tuberculosis burden, testing by the MODS 
assay of all patients with suspected tuberculosis 
(<5% of whom have culture-positive disease in 
Peru) would be a challenge financially and opera-
tionally. In our targeted, high-risk groups, only 
one MODS culture (collected in one visit) is re-
quired to achieve culture-positive rates of 20%, a 
good return on the investment. Programmatic 
studies are now needed to determine the optimal 
implementation strategy to maximize the effect 
and cost-effectiveness of this tool.
The MODS assay addresses two key gaps in 
resource-limited settings with a high tuberculo-
sis burden: rapid, accurate detection of M. tubercu-
losis and simultaneous identification of multidrug-
resistant tuberculosis. The use of culture-based 
diagnostic techniques for case detection may not 
be the future as envisaged by the International 
Union against Tuberculosis and Lung Disease42; 
promotion of such a strategy may conflict with 
the view that the scale-up of coverage and im-
provement of smear microscopy is currently a 
more important priority. However, we believe the 
MODS assay could now be implemented in set-
tings in which smear microscopy is being opti-
mally used and the augmentation of case detec-
tion is feasible and desirable.
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